The first new treatment for Alzheimer's disease has been approved by regulators in the US, paving the way for its use in the UK.
Aducanumab targets the underlying cause of Alzheimer's, the most common form of dementia, rather than its symptoms.
Charities have welcomed the news of a new therapy for the condition.
But scientists are divided over its potential impact because of uncertainty over the trial results.
At least 100,000 people in the UK with a mild form of the disease could be suitable for the drug if it is approved by the UK regulator.
All feeds
